<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Arginine vasopressin resistance (nephrogenic diabetes insipidus): Clinical manifestations and causes
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Daniel G Bichet, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Richard H Sterns, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            John P Forman, MD, MSc
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Feb 08, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H1">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Arginine vasopressin resistance (AVP-R), previously called nephrogenic diabetes insipidus [
         <a href="#rid1">
          1
         </a>
         ], refers to a decrease in urinary concentrating ability that results from resistance to the action of antidiuretic hormone (ADH, also known as arginine vasopressin [AVP]). This problem can reflect resistance at the ADH site of action in the collecting tubules, or interference with the countercurrent mechanism due, for example, to medullary injury or to decreased sodium chloride reabsorption in the medullary aspect of the thick ascending limb of the loop of Henle  (
         <a class="graphic graphic_figure graphicRef51077" href="/z/d/graphic/51077.html" rel="external">
          figure 1
         </a>
         ) [
         <a href="#rid2">
          2
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">
          "Evaluation of patients with polyuria"
         </a>
         .)
        </p>
        <p>
         AVP-R, in its mild form, is relatively common since almost all patients who are older adults, sick, or have acute or chronic kidney disease have a reduction in maximum concentrating ability [
         <a href="#rid2">
          2
         </a>
         ]. As an example, the maximum urine osmolality that can be achieved may fall from the normal value of 800 to 1200 mosmol/kg down to 350 to 600 mosmol/kg in these settings [
         <a href="#rid2">
          2
         </a>
         ]. In chronic kidney disease, this defect is due in part to increased solute excretion per functioning nephron and to decreased expression of mRNA for the V2 vasopressin receptor [
         <a href="#rid2">
          2,3
         </a>
         ].
        </p>
        <p>
         The clinical manifestations and causes of AVP-R will be reviewed here. The treatment of AVP-R, the diagnostic approach to polyuria, and the clinical manifestations and causes of arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) are discussed separately:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">
          "Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">
          "Evaluation of patients with polyuria"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         (See
         <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">
          "Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H141708491">
         <span class="h1">
          CLINICAL MANIFESTATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Patients with moderate to severe AVP-R or AVP-D typically present with polyuria, nocturia, and polydipsia. Polyuria is arbitrarily defined as a urine output exceeding 3 L/day in adults or 2 L/m
         <sup>
          2
         </sup>
         in children.
        </p>
        <p>
         Causes of polyuria other than AVP-R and AVP-D include primary polydipsia and increased solute excretion due to one or more of the following: glucosuria in uncontrolled diabetes mellitus, glucosuria resulting from administration of sodium-glucose cotransporter 2 (SGLT2) inhibitors [
         <a href="#rid4">
          4,5
         </a>
         ], urea with a high-protein diet or after urea administration to treat hyponatremia [
         <a href="#rid6">
          6
         </a>
         ], or sodium chloride and urea in a postobstructive diuresis. In addition, glucosuria can contribute to polyuria in patients with severe AVP-R or AVP-D when hyperglycemia is induced by the administration of large volumes of
         <a class="drug drug_general" data-topicid="8711" href="/z/d/drug information/8711.html" rel="external">
          intravenous dextrose
         </a>
         in water. (See
         <a class="medical medical_review" href="/z/d/html/2381.html" rel="external">
          "Evaluation of patients with polyuria", section on 'Solute (osmotic) diuresis'
         </a>
         .)
        </p>
        <p>
         The urine is normally most concentrated in the morning due to lack of fluid ingestion overnight and increased vasopressin secretion during the late sleep period [
         <a href="#rid7">
          7
         </a>
         ]. As a result, the first manifestation of a mild to moderate loss of concentrating ability is often nocturia. However, nocturia is not diagnostic of a defect in concentrating ability since it can also be caused by other factors such as drinking before going to bed or, in men, by prostatic hypertrophy, which is characterized by urinary frequency rather than polyuria.
        </p>
        <p>
         The serum sodium in untreated patients with AVP-R is often in the high normal range to provide the stimulus for thirst to replace the urinary water losses. Moderate to severe hypernatremia can develop when thirst is impaired or cannot be expressed. This can occur in patients with central nervous system lesions who also have hypodipsia or adipsia, in infants, young children, and neurologically impaired adults who cannot independently access free water, and in the postoperative period in patients with unrecognized AVP-R. (See
         <a class="medical medical_review" href="/z/d/html/2376.html" rel="external">
          "Etiology and evaluation of hypernatremia in adults", section on 'Adipsic diabetes insipidus'
         </a>
         .)
        </p>
        <p>
         Patients with AVP-R may also have manifestations related to the underlying cause, such as
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         toxicity, hypercalcemia, and hypokalemia.
        </p>
        <p class="headingAnchor" id="H2">
         <span class="h1">
          CAUSES
         </span>
         <span class="headingEndMark">
          —
         </span>
         The most common causes of antidiuretic hormone (ADH, also known as arginine vasopressin [AVP]) resistance severe enough to produce polyuria are hereditary AVP-R in children, and chronic
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         ingestion and hypercalcemia in adults. Acquired causes are often at least partially reversible with cessation of the offending drug or correction of hypercalcemia [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H3">
         <span class="h2">
          Hereditary AVP-R
         </span>
         <span class="headingEndMark">
          —
         </span>
         Hereditary AVP-R is an uncommon disorder resulting in variable degrees of resistance to ADH [
         <a href="#rid9">
          9-13
         </a>
         ]. There are two different receptors for ADH: the V1 (AVPR1) and V2 (AVPR2) receptors. The
         <em>
          AVPR2
         </em>
         gene is located on the X chromosome (Xq-28).
        </p>
        <p>
         Activation of the V1 receptors induces vasoconstriction and enhancement of prostaglandin release [
         <a href="#rid2">
          2
         </a>
         ], while the V2 receptors mediate the antidiuretic response as well as peripheral vasodilation and the release of factor VIIIc and von Willebrand's factor from endothelial cells  (
         <a class="graphic graphic_figure graphicRef79887" href="/z/d/graphic/79887.html" rel="external">
          figure 2
         </a>
         ) [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         There are also several congenital polyuric-polydipsic Bartter-like syndromes associated with urinary concentrating defects of varying severity. (See
         <a class="local">
          'Other inherited disorders'
         </a>
         below and
         <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">
          "Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H4">
         <span class="h3">
          Vasopressin V2 receptor gene mutations
         </span>
         <span class="headingEndMark">
          —
         </span>
         Approximately 90 percent of cases of hereditary AVP-R have X-linked inheritance [
         <a href="#rid15">
          15,16
         </a>
         ]. They are due to mutations in the
         <em>
          AVPR2
         </em>
         gene, which encodes for a dysfunctional vasopressin V2 receptor (V2R).
        </p>
        <p>
         Several hundred putative disease-causing
         <em>
          AVPR2
         </em>
         mutations have been identified in ancestrally independent families. Most of these mutant proteins are misfolded, trapped in the endoplasmic reticulum and unable to reach the basolateral cell surface of the principal cells of the collecting ducts to engage circulating vasopressin [
         <a href="#rid10">
          10
         </a>
         ]. In patients with
         <em>
          AVPR2
         </em>
         mutations, the antidiuretic, vasodilator, and coagulation factor responses to ADH are impaired, while the vasoconstrictor and prostaglandin effects are intact [
         <a href="#rid14">
          14
         </a>
         ].
        </p>
        <p>
         The X-linked inheritance means that males tend to have more pronounced polyuria. Female carriers are usually asymptomatic because they have a normal gene on the second X chromosome. However, occasional females have severe polyuria. The presumed mechanism is that X chromosome inactivation is skewed in such a way that the normal X chromosome is preferentially inactivated, leaving the mutant X chromosome dominantly expressed in the kidney [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
         Although heterozygous female individuals may be asymptomatic most of the time, they may develop polyuria during pregnancy when vasopressinases released from the placenta markedly increase the clearance of endogenous ADH. (See
         <a class="medical medical_review" href="/z/d/html/115441.html" rel="external">
          "Polyuria and diabetes insipidus of pregnancy"
         </a>
         .)
        </p>
        <p>
         There is no specific therapy for X-linked AVP-R due to mutations in the
         <em>
          AVPR2
         </em>
         gene. However, studies in a mouse model in which the V2 vasopressin receptors were deleted showed that activation of kidney EP4 prostaglandin E2 receptors with a selective agonist could compensate for the lack of functional V2 receptors and could markedly reduce all of the manifestations of the disease, including the polyuria and alterations in kidney morphology [
         <a href="#rid19">
          19
         </a>
         ]. In the same mouse model,
         <a class="drug drug_general" data-topicid="9621" href="/z/d/drug information/9621.html" rel="external">
          metformin
         </a>
         , an adenosine monophosphate kinase activator, also increased urine osmolality, probably bypassing the V2 receptor and directly phosphorylating aquaporin-2 [
         <a href="#rid20">
          20
         </a>
         ]. In addition, nonpeptide vasopressin receptor agonists have been identified that can activate the mutant V2 receptors at their intracellular sites [
         <a href="#rid21">
          21
         </a>
         ]. These and other treatment issues in patients with AVP-R are discussed elsewhere. (See
         <a class="medical medical_review" href="/z/d/html/2382.html" rel="external">
          "Arginine vasopressin resistance (nephrogenic diabetes insipidus): Treatment", section on 'Treatment'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H5">
         <span class="h3">
          Aquaporin-2 gene mutation
         </span>
         <span class="headingEndMark">
          —
         </span>
         A second form of hereditary AVP-R is caused by a defect in the aquaporin-2 gene that encodes the ADH-sensitive water channels in the collecting tubule cells. This variant may have autosomal recessive or autosomal dominant modes of inheritance [
         <a href="#rid11">
          11,13,15,17,22-30
         </a>
         ].
        </p>
        <p>
         Aquaporin-2 channels are normally stored in the cytosol. Under the influence of ADH, the aquaporin-2 water channels are phosphorylated at Ser-256, Ser-264, and Ser-269 [
         <a href="#rid31">
          31,32
         </a>
         ] and redistributed to the apical (luminal) membrane, thereby allowing water to be reabsorbed down the favorable concentration gradient from the tubular fluid into the hypertonic medullary interstitium [
         <a href="#rid26">
          26,27,33
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2307.html" rel="external">
          "General principles of disorders of water balance (hyponatremia and hypernatremia) and sodium balance (hypovolemia and edema)", section on 'Regulation of plasma tonicity'
         </a>
         .)
        </p>
        <p>
         In one kindred, the autosomal dominant form of AVP-R was mediated by lack of phosphorylation of the aquaporin-2 water channel [
         <a href="#rid34">
          34
         </a>
         ]. Such defects impair trafficking of the water channels, preventing their fusion with the luminal membrane, and decrease channel function [
         <a href="#rid11">
          11,15,23,29
         </a>
         ].
        </p>
        <p>
         Inherited defects of the aquaporin-2 water channel can be distinguished clinically from the more common V2 receptor defect by evaluating, in male patients, the extrarenal responses to ADH: vasodilation and release of factor VIIIc and von Willebrand's factor from endothelial cells [
         <a href="#rid29">
          29,35
         </a>
         ]. These responses are intact in patients with defective water channels and impaired in patients with defective V2 receptors. Molecular genetic testing is also available [
         <a href="#rid13">
          13,17
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H6">
         <span class="h2">
          Lithium toxicity
         </span>
         <span class="headingEndMark">
          —
         </span>
         Polyuria due to impaired urinary concentrating ability occurs in up to 20 percent of patients treated with chronic
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         therapy; an additional 30 percent have a subclinical impairment in concentrating ability. These adverse effects are mediated by lithium entry into the principal cells in the collecting tubule via the epithelial sodium channel (ENaC) [
         <a href="#rid36">
          36
         </a>
         ]. At cytotoxic concentrations, lithium inhibits signaling pathways that involve glycogen synthase kinase type 3 beta (GSK3beta), resulting in dysfunction of the aquaporin-2 water channel  (
         <a class="graphic graphic_figure graphicRef119144" href="/z/d/graphic/119144.html" rel="external">
          figure 3
         </a>
         ) [
         <a href="#rid36">
          36
         </a>
         ]. GSK3beta knock-out mice have a reduced response to vasopressin administration [
         <a href="#rid37">
          37
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2358.html" rel="external">
          "Renal toxicity of lithium", section on 'Arginine vasopressin resistance (nephrogenic diabetes insipidus)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H7">
         <span class="h2">
          Hypercalcemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         A renal concentrating defect may become clinically apparent if the plasma calcium concentration is persistently above 11 mg/dL (2.75 mmol/L) [
         <a href="#rid2">
          2
         </a>
         ]. This defect, which is generally reversible with correction of the hypercalcemia, may be associated with reductions both in sodium chloride reabsorption in the thick ascending limb of the loop of Henle, thereby interfering with the countercurrent mechanism, and in the ability of ADH to increase collecting tubule water permeability [
         <a href="#rid38">
          38-40
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/832.html" rel="external">
          "Clinical manifestations of hypercalcemia", section on 'Arginine vasopressin resistance'
         </a>
         .)
        </p>
        <p>
         The mechanism by which these changes occur is incompletely understood. Calcium deposition in the medulla with secondary tubulointerstitial injury may play an important role [
         <a href="#rid41">
          41
         </a>
         ]. In addition, activation of the calcium-sensing receptor can directly impair concentrating ability by affecting both the loop of Henle and the collecting tubules [
         <a href="#rid42">
          42
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/838.html" rel="external">
          "Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia"
         </a>
         .)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calcium-sensing receptors are expressed on the
         <strong>
          basolateral
         </strong>
         membrane in the thick ascending limb of the loop of Henle. Activation of these receptors by calcium reduces sodium chloride and calcium reabsorption in the thick ascending limb, an effect that appears to be mediated by the generation of a P450 arachidonic acid metabolite (possibly 20-HETE) which then induces closure of the luminal potassium channel [
         <a href="#rid43">
          43
         </a>
         ]. Inhibition of loop sodium chloride reabsorption impairs generation of the medullary osmotic gradient that is essential for urinary concentration [
         <a href="#rid42">
          42
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         Hypercalcemia also enhances the generation of prostaglandin E2, which can contribute to the impairment in sodium chloride reabsorption in the thick ascending limb [
         <a href="#rid39">
          39,44
         </a>
         ]. This response may be mediated by angiotensin II-induced activation of phospholipase A2 and prostaglandin H synthase-1 [
         <a href="#rid44">
          44
         </a>
         ]. In hypercalcemic rats, the associated polyuria can be abolished by the administration of
         <a class="drug drug_general" data-topicid="9574" href="/z/d/drug information/9574.html" rel="external">
          losartan
         </a>
         , an angiotensin II receptor blocker [
         <a href="#rid44">
          44
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Calcium-sensing receptors are also expressed on the
         <strong>
          luminal
         </strong>
         membrane of the cells of the inner medullary collecting duct (IMCD)  (
         <a class="graphic graphic_figure graphicRef119144" href="/z/d/graphic/119144.html" rel="external">
          figure 3
         </a>
         ). By reducing calcium and sodium reabsorption in the loop of Henle, hypercalcemia is associated with an increase in calcium delivery to the luminal IMCD calcium-sensing receptors; their activation reduces the antidiuretic hormone-induced increase in water permeability [
         <a href="#rid45">
          45
         </a>
         ].
        </p>
        <p>
        </p>
        <p>
         Studies in patients with familial hypocalciuric hypercalcemia have demonstrated the importance of hypercalciuria and/or the calcium-sensing receptor in the concentrating defect associated with hypercalcemia. The primary defect in this disorder is an inactivating mutation of the calcium-sensing receptors leading to a reduction in urinary calcium excretion. Affected patients have normal concentrating ability despite persistent hypercalcemia [
         <a href="#rid46">
          46
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/838.html" rel="external">
          "Disorders of the calcium-sensing receptor: Familial hypocalciuric hypercalcemia and autosomal dominant hypocalcemia"
         </a>
         .)
        </p>
        <p>
         Hypercalcemia may also impair water reabsorption by autophagic degradation of aquaporin-2 [
         <a href="#rid47">
          47
         </a>
         ]. In a rodent study, a large decrease in aquaporin-2 expression was observed in the inner medulla and cortex of hypercalcemic rats compared to control animals [
         <a href="#rid48">
          48
         </a>
         ]. This was associated with an increase in urine output and a reduction in urine osmolality.
        </p>
        <p>
         The concentrating defect induced by hypercalcemia is generally reversible with restoration of a normal serum calcium concentration. However, the defect may persist in patients in whom interstitial nephritis has induced permanent medullary damage.
        </p>
        <p class="headingAnchor" id="H8">
         <span class="h2">
          Hypokalemia
         </span>
         <span class="headingEndMark">
          —
         </span>
         Persistent severe hypokalemia (plasma potassium concentration usually below 3 mEq/L) can impair urinary concentrating ability  (
         <a class="graphic graphic_figure graphicRef119144" href="/z/d/graphic/119144.html" rel="external">
          figure 3
         </a>
         ). As with hypercalcemia, both decreased collecting tubule responsiveness to ADH (which may be mediated by decreased expression of aquaporin-2) and diminished sodium chloride reabsorption in the thick ascending limb have been demonstrated in experimental animals [
         <a href="#rid49">
          49-51
         </a>
         ]. Downregulation of urea transporters may also contribute to the impairment of urinary concentrating ability induced by potassium depletion [
         <a href="#rid52">
          52
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/2295.html" rel="external">
          "Hypokalemia-induced kidney dysfunction", section on 'Impaired urinary concentrating ability'
         </a>
         ). In addition, enhanced autophagic degradation of proteins, most notably aquaporin-2, has been demonstrated to be an early event in hypokalemia-induced AVP-R [
         <a href="#rid53">
          53
         </a>
         ].
        </p>
        <p>
         The concentrating defect is generally less severe than with
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         toxicity or hypercalcemia, and symptomatic polyuria and polydipsia are uncommon [
         <a href="#rid2">
          2
         </a>
         ]. When these symptoms do occur, direct stimulation of thirst (via an unknown mechanism) may play a contributory role [
         <a href="#rid54">
          54
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H9">
         <span class="h2">
          Other
         </span>
         <span class="headingEndMark">
          —
         </span>
         AVP-R has been described in a number of other clinical settings.
        </p>
        <p class="headingAnchor" id="H10">
         <span class="h3">
          Kidney disease
         </span>
         <span class="headingEndMark">
          —
         </span>
         Symptomatic AVP-R can be seen in a variety of kidney diseases, including release of bilateral urinary tract obstruction [
         <a href="#rid55">
          55
         </a>
         ], sickle cell disease or trait, autosomal dominant polycystic kidney disease and medullary cystic kidney disease [
         <a href="#rid56">
          56,57
         </a>
         ], renal amyloidosis [
         <a href="#rid58">
          58
         </a>
         ], and Sjögren's disease [
         <a href="#rid59">
          59
         </a>
         ]. In the last two conditions, amyloid deposits in and lymphocytic infiltration around the collecting tubules are presumably responsible for the decline in ADH responsiveness. (See
         <a class="medical medical_review" href="/z/d/html/7199.html" rel="external">
          "Sickle cell disease effects on the kidney"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1680.html" rel="external">
          "Autosomal dominant polycystic kidney disease (ADPKD): Kidney manifestations", section on 'Concentrating defect'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1685.html" rel="external">
          "Autosomal dominant tubulointerstitial kidney disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/3120.html" rel="external">
          "Renal amyloidosis"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7187.html" rel="external">
          "Kidney disease in primary Sjögren's disease"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/7174.html" rel="external">
          "Clinical manifestations and diagnosis of urinary tract obstruction (UTO) and hydronephrosis", section on 'Prognosis'
         </a>
         .)
        </p>
        <p>
         A decline in urinary concentrating ability is also common in patients with acute or chronic kidney disease. A variety of factors contribute including decreased tubular responsiveness to ADH [
         <a href="#rid60">
          60,61
         </a>
         ], and interference with the countercurrent mechanism in diseases affecting the renal medulla, such as chronic pyelonephritis and analgesic abuse nephropathy. In addition, the decrease in the number of functioning nephrons in patients with acute or chronic kidney disease means that each remaining nephron must excrete a larger proportion of the total solute load. The net result is an osmotic diuresis that limits the ability to concentrate the urine [
         <a href="#rid62">
          62,63
         </a>
         ]. Despite the impairment in concentrating ability, patients with acute or chronic kidney disease do
         <strong>
          not
         </strong>
         usually develop polyuria for at least two reasons: the glomerular filtration rate, and therefore the filtered fluid load, is substantially reduced; and the urine osmolality is usually isosmotic or only slightly hypoosmotic to plasma [
         <a href="#rid61">
          61
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H11">
         <span class="h3">
          Drugs
         </span>
         <span class="headingEndMark">
          —
         </span>
         AVP-R can be caused by a number of drugs other than
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         . These include
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         and
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         which are used to treat cytomegalovirus infection in HIV-infected patients [
         <a href="#rid64">
          64,65
         </a>
         ], and vasopressin V2 receptor antagonists, which induce a transient state of AVP-R that can be used to treat hyponatremia and autosomal dominant polycystic kidney disease [
         <a href="#rid66">
          66-68
         </a>
         ], amphotericin B,
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">
          ofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10179" href="/z/d/drug information/10179.html" rel="external">
          orlistat
         </a>
         , and
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         [
         <a href="#rid8">
          8,69
         </a>
         ]. Drug-induced AVP-R is typically reversible, at least in part [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H12">
         <span class="h3">
          Pregnancy
         </span>
         <span class="headingEndMark">
          —
         </span>
         An unusual form of transient ADH resistance occurs in selected women during the second half of pregnancy, a disorder that has been called gestational diabetes insipidus [
         <a href="#rid70">
          70,71
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/404.html" rel="external">
          "Maternal adaptations to pregnancy: Renal and urinary tract physiology"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H13">
         <span class="h3">
          Craniopharyngioma surgery
         </span>
         <span class="headingEndMark">
          —
         </span>
         Craniopharyngioma has been associated with arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) both before surgery and particularly after surgery [
         <a href="#rid72">
          72
         </a>
         ]. (See
         <a class="medical medical_review" href="/z/d/html/2373.html" rel="external">
          "Arginine vasopressin deficiency (central diabetes insipidus): Etiology, clinical manifestations, and postdiagnostic evaluation"
         </a>
         .)
        </p>
        <p>
         A different mechanism is responsible in at least some patients who develop early polyuria following transfrontal surgery for craniopharyngioma. In this setting, the increase in urine output may result from the release of an ADH precursor from the hypothalamus that competes for but does not activate the antidiuretic vasopressin V2 receptors [
         <a href="#rid73">
          73
         </a>
         ]. These patients initially have high ADH levels by immunoassay, but little or no biological activity and a diminished response to exogenous hormone replacement. Thus, they behave as if they have AVP-R.
        </p>
        <p class="headingAnchor" id="H14">
         <span class="h3">
          Bardet-Biedl syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         Bardet-Biedl syndrome is an autosomal recessive disorder that is characterized by obesity and a number of other abnormalities, including hypogenitalism in males, intellectual disability, retinal dystrophy, polydactyly, kidney malformations (particularly calyceal abnormalities), hypertension and, over time, progressive chronic kidney disease [
         <a href="#rid74">
          74,75
         </a>
         ].
        </p>
        <p>
         Polyuria and polydipsia are among the most common and earliest symptoms [
         <a href="#rid74">
          74
         </a>
         ]. A urinary concentration defect can be detected when kidney function is near normal and in the absence of major cyst formation [
         <a href="#rid76">
          76
         </a>
         ]. Bardet-Biedl derived renal epithelial cells are nonciliated and the vasopressin V2 receptor, which is activated by ADH in normal individuals, is localized in the primary cilium [
         <a href="#rid76">
          76
         </a>
         ]. In in vitro studies, these cells did not respond to luminal vasopressin and did not activate luminal aquaporin-2.
        </p>
        <p class="headingAnchor" id="H15">
         <span class="h3">
          Bartter syndrome
         </span>
         <span class="headingEndMark">
          —
         </span>
         There are several congenital polyuric-polydipsic Bartter syndromes associated with AVP-R of varying severity [
         <a href="#rid15">
          15,77-79
         </a>
         ]. These patients have various degrees of polyuria that may be poorly investigated and confused with "pure" hereditary AVP-R [
         <a href="#rid12">
          12
         </a>
         ]. However, patients with "pure" AVP-R handle sodium and potassium normally in contrast to patients with Bartter syndrome who have renal sodium and potassium wasting. In addition, Bartter syndrome may start prenatally, with polyhydramnios frequently leading to prematurity; in some cases caused by mutations in
         <em>
          MAGED2
         </em>
         , the antenatal Bartter syndrome may be transient [
         <a href="#rid79">
          79
         </a>
         ]. (See
         <a class="local">
          'Hereditary AVP-R'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/2344.html" rel="external">
          "Inherited hypokalemic salt-losing tubulopathies: Pathophysiology and overview of clinical manifestations", section on 'Clinical manifestations'
         </a>
         .)
        </p>
        <p>
         The presence of Bartter syndrome can also be distinguished from "pure" hereditary AVP-R in part by sequencing the carboxyl terminus or the last exons of
         <em>
          SLC12A1
         </em>
         and
         <em>
          KCNJ1
         </em>
         (which are two of the five genes underlying Bartter syndrome) [
         <a href="#rid12">
          12
         </a>
         ]. This approach may be informative because most mutations in
         <em>
          SLC12A1
         </em>
         and
         <em>
          KCNJ1
         </em>
         are found in the carboxyl terminus or in the last exon, and, as a consequence, are amenable to rapid DNA sequencing.
        </p>
        <p class="headingAnchor" id="H16">
         <span class="h3">
          Other inherited disorders
         </span>
         <span class="headingEndMark">
          —
         </span>
         Other inherited disorders with a mild, moderate, or severe inability to concentrate the urine include nephronophthisis [
         <a href="#rid80">
          80,81
         </a>
         ], cystinosis [
         <a href="#rid82">
          82
         </a>
         ], familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC) [
         <a href="#rid83">
          83
         </a>
         ], and the syndrome of apparent mineralocorticoid excess in which the polyuria is presumed to be due to chronic hypokalemia, as described above [
         <a href="#rid84">
          84,85
         </a>
         ] (see
         <a class="medical medical_review" href="/z/d/html/6132.html" rel="external">
          "Clinical manifestations, diagnosis, and treatment of nephronophthisis", section on 'Renal disease'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/6139.html" rel="external">
          "Cystinosis", section on 'Renal manifestations'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/2346.html" rel="external">
          "Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)"
         </a>
         and
         <a class="local">
          'Hypokalemia'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/829.html" rel="external">
          "Hypomagnesemia: Causes of hypomagnesemia", section on 'Familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC)'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/829.html" rel="external">
          "Hypomagnesemia: Causes of hypomagnesemia"
         </a>
         ). The ARC syndrome (arthrogryposis-renal dysfunction-cholestasis), a rare autosomal recessive multisystem disorder caused by mutations in
         <em>
          VPS33B
         </em>
         [
         <a href="#rid86">
          86
         </a>
         ] and
         <em>
          VIPAR
         </em>
         [
         <a href="#rid87">
          87
         </a>
         ], is also associated with renal tubular dysfunction, medullary nephrocalcinosis, and AVP-R.
        </p>
        <p class="headingAnchor" id="H1023204186">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/109733.html" rel="external">
          "Society guideline links: Fluid and electrolyte disorders in adults"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H169634970">
         <span class="h1">
          INFORMATION FOR PATIENTS
         </span>
         <span class="headingEndMark">
          —
         </span>
         UpToDate offers two types of patient education materials, "The Basics" and "Beyond the Basics." The Basics patient education pieces are written in plain language, at the 5
         <sup>
          th
         </sup>
         to 6
         <sup>
          th
         </sup>
         grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10
         <sup>
          th
         </sup>
         to 12
         <sup>
          th
         </sup>
         grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.
        </p>
        <p>
         Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on "patient info" and the keyword(s) of interest.)
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Basics topics (see
         <a class="medical medical_basics" href="/z/d/html/17196.html" rel="external">
          "Patient education: Arginine vasopressin disorders (The Basics)"
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H578595">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Arginine vasopressin resistance (AVP-R, previously called nephrogenic diabetes insipidus) refers to a decrease in urinary concentrating ability that results from resistance to the action of antidiuretic hormone (ADH, also known as arginine vasopressin [AVP]). This problem can reflect resistance at the ADH site of action in the collecting tubules, or interference with the countercurrent mechanism due, for example, to medullary injury or to decreased sodium chloride reabsorption in the medullary aspect of the thick ascending limb of the loop of Henle  (
         <a class="graphic graphic_figure graphicRef51077" href="/z/d/graphic/51077.html" rel="external">
          figure 1
         </a>
         ). (See
         <a class="local">
          'Introduction'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Patients with moderate to severe AVP-R or arginine vasopressin deficiency (AVP-D, previously called central diabetes insipidus) typically present with polyuria, nocturia, and polydipsia. The first manifestation of a mild to moderate loss of concentrating ability is often nocturia. (See
         <a class="local">
          'Clinical manifestations'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The most common causes of AVP-R in children are genetic mutations; in adults, AVP-R is most often due to drugs, hypercalcemia, and hypokalemia. (See
         <a class="local">
          'Causes'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Mutations in the vasopressin V2 receptor (V2R) gene, which is X-linked, and the aquaporin-2 gene, which is autosomal, are the two most frequent causes of hereditary AVP-R. (See
         <a class="local">
          'Hereditary AVP-R'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acquired symptomatic AVP-R occurring in adults is usually due to
         <a class="drug drug_general" data-topicid="9566" href="/z/d/drug information/9566.html" rel="external">
          lithium
         </a>
         toxicity or hypercalcemia  (
         <a class="graphic graphic_figure graphicRef119144" href="/z/d/graphic/119144.html" rel="external">
          figure 3
         </a>
         ). The polyuria in these settings is at least partially reversible with cessation of lithium or correction of the hypercalcemia. (See
         <a class="local">
          'Lithium toxicity'
         </a>
         above and
         <a class="local">
          'Hypercalcemia'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Less frequent causes of AVP-R include a variety of genetic and acquired conditions, including:
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Kidney diseases such as bilateral urinary tract obstruction, sickle cell disease or trait, renal amyloidosis, and Sjögren's disease. (See
         <a class="local">
          'Kidney disease'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Use of
         <a class="drug drug_general" data-topicid="9264" href="/z/d/drug information/9264.html" rel="external">
          cidofovir
         </a>
         ,
         <a class="drug drug_general" data-topicid="8476" href="/z/d/drug information/8476.html" rel="external">
          foscarnet
         </a>
         , vasopressin V2 receptor (V2R) antagonists, amphotericin B,
         <a class="drug drug_general" data-topicid="9328" href="/z/d/drug information/9328.html" rel="external">
          demeclocycline
         </a>
         ,
         <a class="drug drug_general" data-topicid="8552" href="/z/d/drug information/8552.html" rel="external">
          ifosfamide
         </a>
         ,
         <a class="drug drug_general" data-topicid="9715" href="/z/d/drug information/9715.html" rel="external">
          ofloxacin
         </a>
         ,
         <a class="drug drug_general" data-topicid="10179" href="/z/d/drug information/10179.html" rel="external">
          orlistat
         </a>
         , and
         <a class="drug drug_general" data-topicid="9351" href="/z/d/drug information/9351.html" rel="external">
          didanosine
         </a>
         . (See
         <a class="local">
          'Drugs'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Pregnancy, which is associated with release of a vasopressinase from the placenta. (See
         <a class="local">
          'Pregnancy'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Craniopharyngioma surgery. (See
         <a class="local">
          'Craniopharyngioma surgery'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent2">
         <span class="glyph">
          •
         </span>
         Bardet-Biedl syndrome, Bartter syndrome, nephronophthisis, cystinosis, familial hypomagnesemia with hypercalciuria and nephrocalcinosis (FHHNC), and the syndrome of apparent mineralocorticoid excess. (See
         <a class="local">
          'Bardet-Biedl syndrome'
         </a>
         above and
         <a class="local">
          'Bartter syndrome'
         </a>
         above and
         <a class="local">
          'Other inherited disorders'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Arima H, Cheetham T, Christ-Crain M, et al. Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus. J Clin Endocrinol Metab 2022; 108:1.
          </a>
         </li>
         <li class="breakAll">
          Rose BD, Post TW. Clinical Physiology of Acid-Base and Electrolyte Disorders, 5th ed, McGraw-Hill, New York 2001. p.754.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Teitelbaum I, McGuinness S. Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA. J Clin Invest 1995; 96:378.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Refardt J, Imber C, Sailer CO, et al. A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis. J Am Soc Nephrol 2020; 31:615.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bichet DG. What is the role of vaptans in routine clinical nephrology? Clin J Am Soc Nephrol 2012; 7:700.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rondon-Berrios H, Tandukar S, Mor MK, et al. Urea for the Treatment of Hyponatremia. Clin J Am Soc Nephrol 2018; 13:1627.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trudel E, Bourque CW. Central clock excites vasopressin neurons by waking osmosensory afferents during late sleep. Nat Neurosci 2010; 13:467.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Garofeanu CG, Weir M, Rosas-Arellano MP, et al. Causes of reversible nephrogenic diabetes insipidus: a systematic review. Am J Kidney Dis 2005; 45:626.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Lieburg AF, Knoers NV, Monnens LA. Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1999; 10:1958.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Morello JP, Salahpour A, Laperrière A, et al. Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants. J Clin Invest 2000; 105:887.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Devonald MA, Karet FE. Renal epithelial traffic jams and one-way streets. J Am Soc Nephrol 2004; 15:1370.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bichet DG. Hereditary polyuric disorders: new concepts and differential diagnosis. Semin Nephrol 2006; 26:224.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bockenhauer D, Bichet DG. Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus. Nat Rev Nephrol 2015; 11:576.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bichet DG, Razi M, Lonergan M, et al. Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus. N Engl J Med 1988; 318:881.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fujiwara TM, Bichet DG. Molecular biology of hereditary diabetes insipidus. J Am Soc Nephrol 2005; 16:2836.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bichet DG. Vasopressin receptor mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28:245.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sasaki S. Nephrogenic diabetes insipidus: update of genetic and clinical aspects. Nephrol Dial Transplant 2004; 19:1351.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nomura Y, Onigata K, Nagashima T, et al. Detection of skewed X-inactivation in two female carriers of vasopressin type 2 receptor gene mutation. J Clin Endocrinol Metab 1997; 82:3434.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Li JH, Chou CL, Li B, et al. A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus. J Clin Invest 2009; 119:3115.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Klein JD, Wang Y, Blount MA, et al. Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts. Am J Physiol Renal Physiol 2016; 310:F1008.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Robben JH, Kortenoeven ML, Sze M, et al. Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists. Proc Natl Acad Sci U S A 2009; 106:12195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wesche D, Deen PM, Knoers NV. Congenital nephrogenic diabetes insipidus: the current state of affairs. Pediatr Nephrol 2012; 27:2183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deen PM, Verdijk MA, Knoers NV, et al. Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine. Science 1994; 264:92.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Deen PM, Croes H, van Aubel RA, et al. Water channels encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are impaired in their cellular routing. J Clin Invest 1995; 95:2291.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Asai T, Kuwahara M, Kurihara H, et al. Pathogenesis of nephrogenic diabetes insipidus by aquaporin-2 C-terminus mutations. Kidney Int 2003; 64:2.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Yamamoto T, Sasaki S. Aquaporins in the kidney: emerging new aspects. Kidney Int 1998; 54:1041.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kozono D, Yasui M, King LS, Agre P. Aquaporin water channels: atomic structure molecular dynamics meet clinical medicine. J Clin Invest 2002; 109:1395.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Oksche A, Möller A, Dickson J, et al. Two novel mutations in the aquaporin-2 and the vasopressin V2 receptor genes in patients with congenital nephrogenic diabetes insipidus. Hum Genet 1996; 98:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hochberg Z, Van Lieburg A, Even L, et al. Autosomal recessive nephrogenic diabetes insipidus caused by an aquaporin-2 mutation. J Clin Endocrinol Metab 1997; 82:686.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Loonen AJ, Knoers NV, van Os CH, Deen PM. Aquaporin 2 mutations in nephrogenic diabetes insipidus. Semin Nephrol 2008; 28:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fenton RA, Moeller HB, Hoffert JD, et al. Acute regulation of aquaporin-2 phosphorylation at Ser-264 by vasopressin. Proc Natl Acad Sci U S A 2008; 105:3134.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tamma G, Robben JH, Trimpert C, et al. Regulation of AQP2 localization by S256 and S261 phosphorylation and ubiquitination. Am J Physiol Cell Physiol 2011; 300:C636.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Nielsen S, Kwon TH, Christensen BM, et al. Physiology and pathophysiology of renal aquaporins. J Am Soc Nephrol 1999; 10:647.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           de Mattia F, Savelkoul PJ, Kamsteeg EJ, et al. Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus. J Am Soc Nephrol 2005; 16:2872.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bichet DG, Oksche A, Rosenthal W. Congenital nephrogenic diabetes insipidus. J Am Soc Nephrol 1997; 8:1951.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Grünfeld JP, Rossier BC. Lithium nephrotoxicity revisited. Nat Rev Nephrol 2009; 5:270.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rao R, Patel S, Hao C, et al. GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity. J Am Soc Nephrol 2010; 21:428.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berl T. The cAMP system in vasopressin-sensitive nephron segments of the vitamin D-treated rat. Kidney Int 1987; 31:1065.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peterson LN, McKay AJ, Borzecki JS. Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcemia. J Clin Invest 1993; 91:2399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Christ-Crain M, Bichet DG, Fenske WK, et al. Diabetes insipidus. Nat Rev Dis Primers 2019; 5:54.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Rosen S, Greenfeld Z, Bernheim J, et al. Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury. Kidney Int 1990; 37:1067.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hebert SC. Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney. Kidney Int 1996; 50:2129.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wang WH, Lu M, Hebert SC. Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol 1996; 271:C103.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Mangat H, Peterson LN, Burns KD. Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors. J Clin Invest 1997; 100:1941.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sands JM, Naruse M, Baum M, et al. Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct. J Clin Invest 1997; 99:1399.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brown EM, Hebert SC. A cloned Ca(2+)-sensing receptor: a mediator of direct effects of extracellular Ca2+ on renal function? J Am Soc Nephrol 1995; 6:1530.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khositseth S, Charngkaew K, Boonkrai C, et al. Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus. Kidney Int 2017; 91:1070.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Earm JH, Christensen BM, Frøkiaer J, et al. Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats. J Am Soc Nephrol 1998; 9:2181.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marples D, Frøkiaer J, Dørup J, et al. Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex. J Clin Invest 1996; 97:1960.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Luke RG, Booker BB, Galla JH. Effect of potassium depletion on chloride transport in the loop of Henle in the rat. Am J Physiol 1985; 248:F682.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Elkjaer ML, Kwon TH, Wang W, et al. Altered expression of renal NHE3, TSC, BSC-1, and ENaC subunits in potassium-depleted rats. Am J Physiol Renal Physiol 2002; 283:F1376.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jung JY, Madsen KM, Han KH, et al. Expression of urea transporters in potassium-depleted mouse kidney. Am J Physiol Renal Physiol 2003; 285:F1210.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Khositseth S, Uawithya P, Somparn P, et al. Autophagic degradation of aquaporin-2 is an early event in hypokalemia-induced nephrogenic diabetes insipidus. Sci Rep 2015; 5:18311.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berl T, Linas SL, Aisenbrey GA, Anderson RJ. On the mechanism of polyuria in potassium depletion. The role of polydipsia. J Clin Invest 1977; 60:620.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Frøkiaer J, Marples D, Knepper MA, Nielsen S. Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney. Am J Physiol 1996; 270:F657.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gabow PA, Kaehny WD, Johnson AM, et al. The clinical utility of renal concentrating capacity in polycystic kidney disease. Kidney Int 1989; 35:675.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Scolari F, Caridi G, Rampoldi L, et al. Uromodulin storage diseases: clinical aspects and mechanisms. Am J Kidney Dis 2004; 44:987.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           CARONE FA, EPSTEIN FH. Nephrogenic diabetes insipidus caused by amyloid disease. Evidence in man of the role of the collecting ducts in concentrating urine. Am J Med 1960; 29:539.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           SHEARN MA, TU WH. NEPHROGENIC DIABETIC INSIPIDUS AND OTHER DEFECTS OF RENAL TUBULAR FUNCTION IN SJOERGREN'S SYNDROME. Am J Med 1965; 39:312.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fine LG, Schlondorff D, Trizna W, et al. Functional profile of the isolated uremic nephron. Impaired water permeability and adenylate cyclase responsiveness of the cortical collecting tubule to vasopressin. J Clin Invest 1978; 61:1519.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannen RL, Regal EM, Dunn MJ, Schrier RW. Vasopressin-resistant hyposthenuria in advanced chronic renal disease. N Engl J Med 1969; 280:1135.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           KLEEMAN CR, ADAMS DA, MAXWELL MH. An evaluation of maximal water diuresis in chronic renal disease. I. Normal solute intake. J Lab Clin Med 1961; 58:169.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           DORHOUT MEES EJ. Relation between maximal urine concentration, maximal water reabsorption capacity, and mannitol clearance in patients with renal disease. Br Med J 1959; 1:1159.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schliefer K, Rockstroh JK, Spengler U, Sauerbruch T. Nephrogenic diabetes insipidus in a patient taking cidofovir. Lancet 1997; 350:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Navarro JF, Quereda C, Quereda C, et al. Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy. Am J Kidney Dis 1996; 27:431.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Schrier RW, Gross P, Gheorghiade M, et al. Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia. N Engl J Med 2006; 355:2099.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Berl T, Quittnat-Pelletier F, Verbalis JG, et al. Oral tolvaptan is safe and effective in chronic hyponatremia. J Am Soc Nephrol 2010; 21:705.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Torres VE, Chapman AB, Devuyst O, et al. Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease. N Engl J Med 2017; 377:1930.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           D'Ythurbide G, Goujard C, Méchaï F, et al. Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review. Nephrol Dial Transplant 2007; 22:3656.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Brewster UC, Hayslett JP. Diabetes insipidus in the third trimester of pregnancy. Obstet Gynecol 2005; 105:1173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Aleksandrov N, Audibert F, Bedard MJ, et al. Gestational diabetes insipidus: a review of an underdiagnosed condition. J Obstet Gynaecol Can 2010; 32:225.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ghirardello S, Hopper N, Albanese A, Maghnie M. Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders. J Pediatr Endocrinol Metab 2006; 19 Suppl 1:413.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Seckl JR, Dunger DB, Bevan JS, et al. Vasopressin antagonist in early postoperative diabetes insipidus. Lancet 1990; 335:1353.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Anadoliiska A, Roussinov D. Clinical aspects of renal involvement in Bardet-Biedl syndrome. Int Urol Nephrol 1993; 25:509.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Parfrey PS, Davidson WS, Green JS. Clinical and genetic epidemiology of inherited renal disease in Newfoundland. Kidney Int 2002; 61:1925.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Marion V, Schlicht D, Mockel A, et al. Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption. Kidney Int 2011; 79:1013.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Peters M, Jeck N, Reinalter S, et al. Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies. Am J Med 2002; 112:183.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeck N, Schlingmann KP, Reinalter SC, et al. Salt handling in the distal nephron: lessons learned from inherited human disorders. Am J Physiol Regul Integr Comp Physiol 2005; 288:R782.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Laghmani K, Beck BB, Yang SS, et al. Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations. N Engl J Med 2016; 374:1853.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Hildebrandt F, Attanasio M, Otto E. Nephronophthisis: disease mechanisms of a ciliopathy. J Am Soc Nephrol 2009; 20:23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bodaghi E, Honarmand MT, Ahmadi M. Infantile nephronophthisis. Int J Pediatr Nephrol 1987; 8:207.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Knoepfelmacher M, Rocha R, Salgado LR, et al. [Nephropathic cystinosis: report of 2 cases and review of the literature]. Rev Assoc Med Bras (1992) 1994; 40:43.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Praga M, Vara J, González-Parra E, et al. Familial hypomagnesemia with hypercalciuria and nephrocalcinosis. Kidney Int 1995; 47:1419.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dave-Sharma S, Wilson RC, Harbison MD, et al. Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess. J Clin Endocrinol Metab 1998; 83:2244.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bockenhauer D, van't Hoff W, Dattani M, et al. Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases. Nephron Physiol 2010; 116:p23.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Gissen P, Johnson CA, Morgan NV, et al. Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome. Nat Genet 2004; 36:400.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Cullinane AR, Straatman-Iwanowska A, Zaucker A, et al. Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization. Nat Genet 2010; 42:303.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 2289 Version 21.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36355385" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/36355385" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Changing the Name of Diabetes Insipidus: A Position Statement of the Working Group for Renaming Diabetes Insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7615808" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Vasopressin resistance in chronic renal failure. Evidence for the role of decreased V2 receptor mRNA.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/32019783" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : A Randomized Trial of Empagliflozin to Increase Plasma Sodium Levels in Patients with the Syndrome of Inappropriate Antidiuresis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22516285" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : What is the role of vaptans in routine clinical nephrology?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/30181129" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Urea for the Treatment of Hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20190744" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Central clock excites vasopressin neurons by waking osmosensory afferents during late sleep.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15806465" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Causes of reversible nephrogenic diabetes insipidus: a systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10477148" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Clinical presentation and follow-up of 30 patients with congenital nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10749568" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : Pharmacological chaperones rescue cell-surface expression and function of misfolded V2 vasopressin receptor mutants.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15153548" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Renal epithelial traffic jams and one-way streets.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16713495" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Hereditary polyuric disorders: new concepts and differential diagnosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26077742" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pathophysiology, diagnosis and management of nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2965301" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : Hemodynamic and coagulation responses to 1-desamino[8-D-arginine] vasopressin in patients with congenital nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16093448" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Molecular biology of hereditary diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519085" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : Vasopressin receptor mutations in nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15004257" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : Nephrogenic diabetes insipidus: update of genetic and clinical aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329382" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Detection of skewed X-inactivation in two female carriers of vasopressin type 2 receptor gene mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19729836" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : A selective EP4 PGE2 receptor agonist alleviates disease in a new mouse model of X-linked nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26962099" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Metformin, an AMPK activator, stimulates the phosphorylation of aquaporin 2 and urea transporter A1 in inner medullary collecting ducts.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19587238" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Intracellular activation of vasopressin V2 receptor mutants in nephrogenic diabetes insipidus by nonpeptide agonists.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22427315" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Congenital nephrogenic diabetes insipidus: the current state of affairs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8140421" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Requirement of human renal water channel aquaporin-2 for vasopressin-dependent concentration of urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7537761" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : Water channels encoded by mutant aquaporin-2 genes in nephrogenic diabetes insipidus are impaired in their cellular routing.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12787389" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : Pathogenesis of nephrogenic diabetes insipidus by aquaporin-2 C-terminus mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9767520" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : Aquaporins in the kidney: emerging new aspects.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12045251" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Aquaporin water channels: atomic structure molecular dynamics meet clinical medicine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8882880" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Two novel mutations in the aquaporin-2 and the vasopressin V2 receptor genes in patients with congenital nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9024277" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : Autosomal recessive nephrogenic diabetes insipidus caused by an aquaporin-2 mutation.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18519086" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : Aquaporin 2 mutations in nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18287043" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Acute regulation of aquaporin-2 phosphorylation at Ser-264 by vasopressin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21148409" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Regulation of AQP2 localization by S256 and S261 phosphorylation and ubiquitination.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/10073616" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Physiology and pathophysiology of renal aquaporins.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16120822" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Lack of arginine vasopressin-induced phosphorylation of aquaporin-2 mutant AQP2-R254L explains dominant nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9402099" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Congenital nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19384328" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Lithium nephrotoxicity revisited.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20056751" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : GSK3beta mediates renal response to vasopressin by modulating adenylate cyclase activity.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3037155" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : The cAMP system in vasopressin-sensitive nephron segments of the vitamin D-treated rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8390479" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Endogenous prostaglandin E2 mediates inhibition of rat thick ascending limb Cl reabsorption in chronic hypercalcemia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/31395885" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2342245" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Hypercalcemic nephropathy: chronic disease with predominant medullary inner stripe injury.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8943500" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Extracellular calcium-sensing receptor: implications for calcium and magnesium handling in the kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8760035" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9329957" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : Hypercalcemia stimulates expression of intrarenal phospholipase A2 and prostaglandin H synthase-2 in rats. Role of angiotensin II AT1 receptors.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9077550" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : Apical extracellular calcium/polyvalent cation-sensing receptor regulates vasopressin-elicited water permeability in rat kidney inner medullary collecting duct.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8749677" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : A cloned Ca(2+)-sensing receptor: a mediator of direct effects of extracellular Ca2+ on renal function?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28139295" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Hypercalcemia induces targeted autophagic degradation of aquaporin-2 at the onset of nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9848772" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Decreased aquaporin-2 expression and apical plasma membrane delivery in kidney collecting ducts of polyuric hypercalcemic rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8621781" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Hypokalemia-induced downregulation of aquaporin-2 water channel expression in rat kidney medulla and cortex.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3993792" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Effect of potassium depletion on chloride transport in the loop of Henle in the rat.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12388387" id="rid50" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          51 : Altered expression of renal NHE3, TSC, BSC-1, and ENaC subunits in potassium-depleted rats.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12952854" id="rid51" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          52 : Expression of urea transporters in potassium-depleted mouse kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/26674602" id="rid52" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          53 : Autophagic degradation of aquaporin-2 is an early event in hypokalemia-induced nephrogenic diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/893666" id="rid53" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          54 : On the mechanism of polyuria in potassium depletion. The role of polydipsia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8967344" id="rid54" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          55 : Bilateral ureteral obstruction downregulates expression of vasopressin-sensitive AQP-2 water channel in rat kidney.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/2709672" id="rid55" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          56 : The clinical utility of renal concentrating capacity in polycystic kidney disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15558519" id="rid56" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          57 : Uromodulin storage diseases: clinical aspects and mechanisms.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13807843" id="rid57" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          58 : Nephrogenic diabetes insipidus caused by amyloid disease. Evidence in man of the role of the collecting ducts in concentrating urine.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14320699" id="rid58" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          59 : NEPHROGENIC DIABETIC INSIPIDUS AND OTHER DEFECTS OF RENAL TUBULAR FUNCTION IN SJOERGREN'S SYNDROME.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/207738" id="rid59" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          60 : Functional profile of the isolated uremic nephron. Impaired water permeability and adenylate cyclase responsiveness of the cortical collecting tubule to vasopressin.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/5782121" id="rid60" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          61 : Vasopressin-resistant hyposthenuria in advanced chronic renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13756614" id="rid61" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          62 : An evaluation of maximal water diuresis in chronic renal disease. I. Normal solute intake.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13638656" id="rid62" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          63 : Relation between maximal urine concentration, maximal water reabsorption capacity, and mannitol clearance in patients with renal disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9259663" id="rid63" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          64 : Nephrogenic diabetes insipidus in a patient taking cidofovir.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8604715" id="rid64" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          65 : Nephrogenic diabetes insipidus and renal tubular acidosis secondary to foscarnet therapy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17105757" id="rid65" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          66 : Tolvaptan, a selective oral vasopressin V2-receptor antagonist, for hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20185637" id="rid66" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          67 : Oral tolvaptan is safe and effective in chronic hyponatremia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/29105594" id="rid67" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          68 : Tolvaptan in Later-Stage Autosomal Dominant Polycystic Kidney Disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17905805" id="rid68" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          69 : Fanconi syndrome and nephrogenic diabetes insipidus associated with didanosine therapy in HIV infection: a case report and literature review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15863571" id="rid69" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          70 : Diabetes insipidus in the third trimester of pregnancy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20500966" id="rid70" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          71 : Gestational diabetes insipidus: a review of an underdiagnosed condition.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16700319" id="rid71" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          72 : Diabetes insipidus in craniopharyngioma: postoperative management of water and electrolyte disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/1971658" id="rid72" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          73 : Vasopressin antagonist in early postoperative diabetes insipidus.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8270381" id="rid73" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          74 : Clinical aspects of renal involvement in Bardet-Biedl syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12028433" id="rid74" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          75 : Clinical and genetic epidemiology of inherited renal disease in Newfoundland.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21270763" id="rid75" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          76 : Bardet-Biedl syndrome highlights the major role of the primary cilium in efficient water reabsorption.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11893344" id="rid76" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          77 : Clinical presentation of genetically defined patients with hypokalemic salt-losing tubulopathies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15793031" id="rid77" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          78 : Salt handling in the distal nephron: lessons learned from inherited human disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27120771" id="rid78" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          79 : Polyhydramnios, Transient Antenatal Bartter's Syndrome, and MAGED2 Mutations.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19118152" id="rid79" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          80 : Nephronophthisis: disease mechanisms of a ciliopathy.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3449470" id="rid80" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          81 : Infantile nephronophthisis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/8061694" id="rid81" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          82 : [Nephropathic cystinosis: report of 2 cases and review of the literature].
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/7637271" id="rid82" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          83 : Familial hypomagnesemia with hypercalciuria and nephrocalcinosis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9661590" id="rid83" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          84 : Examination of genotype and phenotype relationships in 14 patients with apparent mineralocorticoid excess.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20733335" id="rid84" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          85 : Secondary nephrogenic diabetes insipidus as a complication of inherited renal diseases.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/15052268" id="rid85" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          86 : Mutations in VPS33B, encoding a regulator of SNARE-dependent membrane fusion, cause arthrogryposis-renal dysfunction-cholestasis (ARC) syndrome.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20190753" id="rid86" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          87 : Mutations in VIPAR cause an arthrogryposis, renal dysfunction and cholestasis syndrome phenotype with defects in epithelial polarization.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
